MedPath

Ganirelix Acetate

Ganirelix Acetate Injection(For Subcutaneous Use Only)

Approved
Approval ID

1f067dfb-f9c7-4020-ab7b-da2ba695ab32

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 6, 2023

Manufacturers
FDA

Meitheal Pharmaceuticals Inc.

DUNS: 080548348

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ganirelix Acetate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code71288-554
Application NumberANDA214996
Product Classification
M
Marketing Category
C73584
G
Generic Name
Ganirelix Acetate
Product Specifications
Route of AdministrationSUBCUTANEOUS
Effective DateJune 6, 2022
FDA Product Classification

INGREDIENTS (5)

ganirelix acetateActive
Quantity: 250 ug in 0.5 mL
Code: 56U7906FQW
Classification: ACTIB
mannitolInactive
Quantity: 23.5 mg in 0.5 mL
Code: 3OWL53L36A
Classification: IACT
acetic acidInactive
Quantity: 0.1 mg in 0.5 mL
Code: Q40Q9N063P
Classification: IACT
sodium hydroxideInactive
Code: 55X04QC32I
Classification: IACT
waterInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Ganirelix Acetate - FDA Drug Approval Details